Dashenlin Pharm Grp Co Ltd - Asset Resilience Ratio
Dashenlin Pharm Grp Co Ltd (603233) has an Asset Resilience Ratio of 0.80% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Dashenlin Pharm Grp Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Dashenlin Pharm Grp Co Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Dashenlin Pharm Grp Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Dashenlin Pharm Grp Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Dashenlin Pharm Grp Co Ltd (603233) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥213.71 Million | 0.8% |
| Total Liquid Assets | CN¥213.71 Million | 0.80% |
Asset Resilience Insights
- Limited Liquidity: Dashenlin Pharm Grp Co Ltd maintains only 0.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dashenlin Pharm Grp Co Ltd Industry Peers by Asset Resilience Ratio
Compare Dashenlin Pharm Grp Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Redcare Pharmacy NV
F:RDC |
Pharmaceutical Retailers | 9.15% |
|
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017 |
Pharmaceutical Retailers | 0.01% |
|
Raia Drogasil S.A
SA:RADL3 |
Pharmaceutical Retailers | 0.38% |
|
Empreendimentos Pague Menos S.A
SA:PGMN3 |
Pharmaceutical Retailers | 0.00% |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3 |
Pharmaceutical Retailers | 2.05% |
|
High Tide Inc
V:HITI |
Pharmaceutical Retailers | 0.03% |
|
Yifeng Pharmacy
SHG:603939 |
Pharmaceutical Retailers | 19.16% |
|
Laobaixing Pharmacy
SHG:603883 |
Pharmaceutical Retailers | 0.01% |
Annual Asset Resilience Ratio for Dashenlin Pharm Grp Co Ltd (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Dashenlin Pharm Grp Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.66% | CN¥438.96 Million ≈ $64.23 Million |
CN¥26.49 Billion ≈ $3.88 Billion |
+1.60pp |
| 2024-12-31 | 0.06% | CN¥15.51 Million ≈ $2.27 Million |
CN¥26.44 Billion ≈ $3.87 Billion |
-0.12pp |
| 2023-12-31 | 0.17% | CN¥41.99 Million ≈ $6.14 Million |
CN¥24.12 Billion ≈ $3.53 Billion |
-0.27pp |
| 2022-12-31 | 0.44% | CN¥91.99 Million ≈ $13.46 Million |
CN¥20.84 Billion ≈ $3.05 Billion |
-0.19pp |
| 2021-12-31 | 0.63% | CN¥109.37 Million ≈ $16.00 Million |
CN¥17.34 Billion ≈ $2.54 Billion |
-4.96pp |
| 2020-12-31 | 5.60% | CN¥689.98 Million ≈ $100.97 Million |
CN¥12.33 Billion ≈ $1.80 Billion |
-6.08pp |
| 2017-12-31 | 11.68% | CN¥680.00 Million ≈ $99.51 Million |
CN¥5.82 Billion ≈ $852.05 Million |
+9.41pp |
| 2014-12-31 | 2.27% | CN¥53.69 Million ≈ $7.86 Million |
CN¥2.37 Billion ≈ $346.10 Million |
-0.30pp |
| 2013-12-31 | 2.57% | CN¥43.20 Million ≈ $6.32 Million |
CN¥1.68 Billion ≈ $245.96 Million |
-1.24pp |
| 2012-12-31 | 3.81% | CN¥37.97 Million ≈ $5.56 Million |
CN¥996.51 Million ≈ $145.82 Million |
-- |
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.